| Literature DB >> 36175900 |
Ying Hu1,2,3, Xingjuan Chen1, Mu Hu1,2, Dongwei Zhang4, Shuo Yuan5, Ping Li6,7, Ling Feng8,9.
Abstract
Dyslipidemia is an independent risk factor of cardiovascular diseases (CVDs), which lead to the high mortality, disability, and medical expenses in the worldwide. Based on the previous researches, the improvement of dyslipidemia could efficiently prevent the occurrence and progress of cardiovascular diseases. Medicinal and edible plants (MEPs) are the characteristics of Chinese medicine, and could be employed for the disease treatment and health care mostly due to their homology of medicine and food. Compared to the lipid-lowering drugs with many adverse effects, such as rhabdomyolysis and impaired liver function, MEPs exhibit the great potential in the treatment of dyslipidemia with high efficiency, good tolerance and commercial value. In this review, we would like to introduce 20 kinds of MEPs with lipid-lowering effect in the following aspects, including the source, function, active component, target and underlying mechanism, which may provide inspiration for the development of new prescription, functional food and complementary therapy for dyslipidemia.Entities:
Keywords: Dyslipidemia; Lipid-lowering; Medicinal and edible plants; Signaling pathway
Year: 2022 PMID: 36175900 PMCID: PMC9522446 DOI: 10.1186/s13020-022-00666-9
Source DB: PubMed Journal: Chin Med ISSN: 1749-8546 Impact factor: 4.546
Fig. 1Schematic diagram of the effects and mechanisms of MEPs in modifying dyslipidemia. HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; MEPs, medicinal and edible plants; TC, total cholesterol; TG, triglyceride; VLDL, very low-density lipoprotein
Fig. 2The target genes and proteins of MEPs in the treatment of dyslipidemia, which involves the process of lipid absorption, synthesis, decomposition and metabolism. Red letters indicate the potential lipid-lowering mechanisms. RCT, reverse cholesterol transport. Materials provided by FigDraw (www.figdraw.com)
Effects and mechanisms of MEPs in the treatment of dyslipidemia
| No | MEPs | Active ingredients | Lipid metabolism | Signaling pathway | Mechanism of action | References |
|---|---|---|---|---|---|---|
| 1 | Polyphenol | ↓TC, TG, LDL; ↑HDL | 1) Inhibit the expressions of SREBP-1c, ACLY, and FAS; 2) Increase the expressions of PPAR-α and IRS | 1) Inhibit triglyceride synthesis; 2) Promote fatty acid oxidation; 3) Increase insulin sensitivity | [ | |
| 2 | Extract | ↓TC, TG, LDL | 1) Downregulate PPAR-γ, SREBP-1c, C/EBP-α, CD36, ACLY, ACC, FAS, SCD1, and DGAT2; 2) Upregulate PPARα and CPT1α; 3) Activate AMPK signaling pathway | 1) Inhibit triglyceride biosynthesis; 2) Increase fatty acid oxidation | [ | |
| Flavonoids, luteolin, luteoloside | ↓TC, TG, LDL, Apo B; ↑Apo A1 | 1) Inhibit the enzymes activity of FAS, HMG-CoA and DGAT; 2) Increase the activity of FAβO, CYP7A1 and HL | 1) Inhibit lipid synthesis; 2) Promote bile acids biosynthesis; 3) Promote fatty acid oxidation | [ | ||
| 3 | Extract | ↓TC | 1) Activate AMPK phosphorylation; 2) Inhibit the activity of HMG-CoA, HMGCR and NPC1L1; | 1) Inhibit cholesterol biosynthesis; 2) Inhibit cholesterol absorption | [ | |
| Polyphenols | ↓TC, TG, LDL, Apo B; ↑HDL, Apo A1 | 1) Inhibit the activity of pCEH, ACAT and CETP; 2) Enhance the activity of LCAT | 1) Inhibit cholesterol esterification and absorption; 2) Improve lipid transport protein system | [ | ||
| Naringin | ↓TC, LDL | 1) Upregulate p-AMPKα and LDLR; 2) Downregulate SREBP-1, SREBP-2, and PCSK9 | 1) Inhibit lipids biosynthesis; 2) Promote cholesterol metabolism | [ | ||
| 4 | Extract; powder; juice | ↓TC, TG, LDL; ↑HDL | 1) Regulate the perturbed metabolism pathways; 2) Inhibit pancreatic lipase; 3) Increase the LCAT activity | 1) Improve gut microflora; 2) Inhibit lipid absorption; 3) Promote reverse cholesterol transport | [ | |
| Pectin penta-oligogalacturonide | / | 1) Inhibit FXR-FGF15 axis; 2) Increase CYP7A1 and ASBT | 1) Promote bile acids biosynthesis; 2) Inhibit intestinal bile acid reabsorption | [ | ||
| Crude glycoprotein | ↓TC, TG; ↑HDL | / | / | [ | ||
| Vitexin | ↓TC, TG | 1) Activate AMPKα; 2) Downregulate C/EBPα and FAS | Inhibit de novo lipogenesis | [ | ||
| 5 | Extract | ↓TC, TG, LDL | 1) Downregulate SREBP-1c, FAS, SCD1, and PPARγ; 2) Upregulate PPARα and CPT-1 | Inhibit biosynthesis of triglyceride and cholesterol | [ | |
| Geniposide | ↓TC, TG, LDL, VLDL, ApoC3; ↑HDL | 1) Enhance the phosphorylation of ACC, AMPKα, and AMPKβ; 2) Upregulate PPARα, LDLR, SR-B1, ABCA1, ABCG1, CYP7A1, CYP27A1, CYP7B1, and CYP8B1; 3) Downregulate SREBP-1c, miR-101 and SR-A; 4) Inhibit FXR-mediated bile acids liver-gut crosstalk | 1) Inhibit triglyceride and cholesterol biosynthesis; 2) Decrease free cholesterol esterification and cholesterol uptake; 3) Promote cholesterol efflux; 4) Facilitate reverse cholesterol transport; 5) Motivate bile acid biosynthesis and excretion | [ | ||
| Genipin | ↓TC, TG ↑HDL | 1) Upregulate the gene expressions of HSL, ATGL, CPT‐1α and PPARα; 2) Downregulate SREBP-1c, FAS, and SCD1 | 1) Promote triglyceride decomposition; 2) Inhibit triglyceride synthesis | [ | ||
| 6 | Flavonoids; isorhamnetin | ↓TG | 1) Upregulate PPARα, LXRα, LDLR, CYP7A1, ABCA1 and CPT1A; 2) Downregulate SREBP-2 | 1) Promote cholesterol metabolism; 2) Inhibit cholesterol de novo synthesis; 3) Accelerate fatty acid oxidation | [ | |
| Kaempferol and kaempferide | ↓TG | Downregulate SREBP-1, FAS, SCD1, PPARγ and C/EBPβ | Inhibit fatty acid synthesis and adipogenesis | [ | ||
| Sterols | ↓TC, TG, LDL; ↑HDL | 1) Increase Apo-A, HL and LPL; 2) Reduce Apo-B | Promote lipids transport and decomposition | [ | ||
| 7 | Extract | ↓TC, TG, LDL; ↑HDL | 1) Downregulate miR-33, miR-21, miR-143, FXR, SHP, SREBP-2, PPARγ, and C/EBPα; 2) Upregulate LXR-α, ABCG5, CYP7A1, ABCA1, ApoA-1 and LCAT; 3) Inhibit GPDH activity; 4) Increase AMPK activity | 1) Inhibit de novo cholesterol biosynthesis; 2) Increase bile acids synthesis; 3) Promote cholesterol reversal transport; 4) Inhibit adipogenesis and adipocyte differentiation | [ | |
| Polysaccharides | ↓TC, TG, LDL; ↑HDL | Selective enrich bacteria and reduce intestinal microbial diversity | Regulate gut microbiota | [ | ||
| 8 | Powder | ↓TC, LDL; ↑HDL | 1) Inhibit FXR expression; 2) Promote CYP7A1 expression; 3) Maintain the ratio of ABCG5/ABCG8 | 1) Promote cholesterol efflux; 2) Promote bile acids biosynthesis and excretion | [ | |
| Extract | ↓TC, TG, LDL; ↑HDL | 1) Increase CYP7A1, LXRα, ABCG5/ABCG8, CPT1 and PPARα expression; 2) Decrease SREBP-1, FAS, AGPAT and miR-33 expression; 3) Increase the AMPK activity | 1) Increase hepatic bile acid biosynthesis; 2) Inhibit lipid biosynthesis; 3) Promote lipid degradation; 4) Promote fecal cholesterol excretion | [ | ||
| Flavonoids; quercetin | ↓TC, TG, LDL; ↑HDL | 1) Activate AMPK-PGC-1α signaling pathway; 2) Downregulate SREBP-2, HMGCR, LXRβ and miR-33a; 3) Increase the expressions of CPT-1 and CYP7A1 | 1) Promote mitochondrial fatty acid oxidation; 2) Improve insulin resistance; 3) Inhibit cholesterol biosynthesis; 4) Promote cholesterol convert to bile acid; | [ | ||
| Polyphenols and fiber | ↓TC, TG, LDL; ↑HDL | 1) Downregulate FAS, C/EBP-α and PPARγ; 2) Improve intestinal flora diversity | 1) Inhibit triglyceride biosynthesis and adipocyte differentiation; 2) Regulate gut microbiota | [ | ||
| Polysaccharides | ↓TC, TG, LDL; ↑HDL | Inhibit pancreatic lipase activity | Inhibit lipids absorption | [ | ||
| 9 | Powder | ↓TC, TG | 1) Downregulate SREBP-1c mRNA; 2) Inhibit HMG-CoA activity; 3) Enhance LPL activity | 1) Inhibit synthesis of triglycerides and cholesterol; 2) Promote triglyceride decomposition | [ | |
| Nuciferine | ↓TC, TG, LDL | 1) Downregulate SREBP-1, ACLY, ACC, FAS, PPARγ, C/EBPα and C/EBPβ; 2) Upregulate LCAT activity and PPARγ/LXRα/ABCA1 pathways; 3) Inhibit PI3K/AKT/mTOR pathways; 4) Alter the diversity and composition of gut microbiota | 1) Inhibit lipids biosynthesis; 2) Increase cholesterol efflux; 3) Promote autophagy and reduce macrophage foaming; 4) Regulate gut microbiota | [ | ||
| 10 | Ethanol extract | ↓TC, TG, LDL, ApoB; ↑ApoA1 | 1) Inhibit the activity of HMGCR; 2) Regulate apolipoprotein; 3) Regulate PPARγ-LPL/ATGL/HSL and FXR-HL pathway | 1) Decrease cholesterol synthesis; 2) Regulate cholesterol transport; 3) promote triglyceride metabolism | [ | |
| Water extract | ↓TC, TG, LDL; ↑HDL | Alter the diversity and composition of gut microbiota | Improve gut microflora | [ | ||
| 11 | Hydroxy-α-sanshool | ↓TC, TG, LDL; ↑HDL | Increase mRNA and protein expression of PPARγ and ApoE | Promote lipid metabolism and lipoprotein transformation | [ | |
| 12 | Diosgenin | ↓TC, TG; ↑HDL | Activate the catabolic pathway via AMPK | Inhibit cholesterol absorption and facilitate cholesterol excretion | [ | |
| Resistant starch | ↓TC, TG, LDL; ↑HDL | Increase the relative abundance of probiotics | Regulate gut microbiota | [ | ||
| 13 | Extract | ↓TC, LDL; ↑HDL | 1) Upregulate CPT-1 mRNA expression; 2) Regulate the composition and concentration of amino acids, carbohydrates and esters | 1) Promote fatty acid β-oxidation; 2) Regulate endogenous metabolites | [ | |
| Polysaccharides | ↓TC, TG, LDL; ↑HDL | 1) Upregulate PPAR-α and PPAR-β; 2) Downregulate PPAR-γ and SREBP-1c; 3) Regulate gut microbiota and restore the intestinal permeability barrier; | 1) Inhibit lipid synthesis; 2) Promote fatty acid oxidation and lipolysis; 3) Regulate gut microbiota | [ | ||
| Saponin | ↓TC, TG, LDL; ↑HDL | Modulate the composition, abundance and diversity of gut microbiota | Regulate gut microbiota | [ | ||
| Syringaresinol‑di‑O‑β‑D‑glucoside | ↓TC, TG, LDL‑C, VLDL‑C, FFA | Promote insulin secretion | Improve insulin sensitivity | [ | ||
| 14 | Total flavonoids | ↓TC, TG, LDL, VLDL; ↑HDL | 1) Upregulate FXR, TGR5, CYP7A1, ASBT, AMPKα and CPT1α; 2) Downregulate FAS and SREBP-1c; | 1) Promote bile acids synthesis and excretion; 2) Enhance fatty acid oxidation; 3) Inhibit lipid synthesis | [ | |
| Astragaloside IV | ↓TC, TG, FFA; ↑HDL | 1) Activate AMPK, ACC and SREBP-1 phosphorylation; 2) Downregulate SREBP-1, ACC1, FAS and SCD1 | Inhibit lipid biosynthesis | [ | ||
| 15 | Extract | ↓TC; ↑HDL | Activate AMPK and PGC-1α proteins | Promote mitochondrial biogenesis and energy metabolism | [ | |
| Puerarin | ↓TC, TG, LDL | 1) Downregulate SREBP-1c, FAS, SCD1 and HMGCR; 2) Upregulate CPT1, ACOX and HL; 3) Increase the phosphorylation of AMPK and ACC | 1) Inhibit triglycerides and cholesterol synthesis; 2) Promote fatty acid oxidation and lipolysis | [ | ||
| Polysaccharides | ↓TC, TG, LDL, FFA; ↑HDL | 1) Downregulate SREBP-1 and ACC; 2) Upregulate PPARα and LDLR; 3) Upregulate FXR, FGFR4, CYP7A1, BSEP, MRP2, and LXR | 1) Inhibit lipid synthesis; 2) Promote β-oxidation; 3) Promote LDL-C degradation; 4) Promote bile acids synthesis and excretion | [ | ||
| 16 | Extract | ↓TC, TG, LDL, | 1) Improve intestinal microbiota composition and barrier damage; 2) Upregulate LDLR mRNA | 1) Regulate gut microbiota; 2) Promote LDL-C degradation | [ | |
| Anthraquinone glycoside | ↓ LDL; ↑HDL | 1) Increase the PPARα expression; 2) Inhibit the SREBP-1c expression | 1) Inhibit triglyceride synthesis; 2) Promote fatty acid oxidation | [ | ||
| 1,8-Dihydroxyanthraquinone | ↓TC, TG, LDL; ↑HDL | 1) Upregulate CYP7A1; 2) Downregulate HMGCR | 1) Inhibit cholesterol synthesis; 2) Promote cholesterol conversion into bile acids | [ | ||
| 17 | Bacillus subtilis-fermented extract | ↓TG | 1) Downregulate aP2, adiponectin, C/EBPα, PPARγ and FAS; 2) Upregulate PPARα, ACOX, LCAD, pHSL and ATG | 1) Inhibit lipid biosynthesis; 2) Promote triglyceride hydrolysis and β-oxidation | [ | |
| Total terpenoids; total flavonoids | ↓TC, TG, LDL; ↑HDL | / | / | [ | ||
| 18 | Extract | ↓TC, TG, LDL, FFA | 1) Downregulate Fsp27/Cidec, VLDLR, CD36, DGAT1 and DGAT2; 2) Increase adiponectin levels; 3) Regulate GL/FFA cycle and bile acid metabolism | 1) Inhibit TG synthesis and fatty acid up-take; 2) Increase FFA oxidation; 3) Improve endogenous metabolites | [ | |
| 19 | Amygdalin | ↓TC, TG, LDL; ↑HDL | / | / | [ | |
| Peach kernel oil | ↓TC, TG, LDL; ↑HDL | / | / | [ | ||
| 20 | Extract/powder | ↓TC, TG, LDL, VLDL; ↑HDL | Upregulate the protein expression of PPAR-α and PPAR-γ | Promote lipolysis and fatty acid oxidation | [ |
Animal models and interventions of MEPs in the treatment of dyslipidemia
| No | MEPs | Intervention | Animal model | Dosage | Period | Control | Dosage | References |
|---|---|---|---|---|---|---|---|---|
| 1 | Powder | Albino Rats | 2 and 4 g/kg | 30 days | / | / | [ | |
| Extract | C57BL/6 J mice | 1% | 14 weeks | / | / | [ | ||
| Polyphenol | Wistar rats | 100 mg/kg | 12 weeks | / | / | [ | ||
| Extract | White mice | 2 mg, 4 mg and 8 mg/20 g | 28 days | / | / | [ | ||
| Extract | Albino Rats | 250 and 500 mg/kg | 7 days | Atorvastatin | 10 mg/kg | [ | ||
| 2 | Extract | SD rats | 0.2% and 0.4% | 13 weeks | / | / | [ | |
| Extract | SD rats | 1, 2 and 4 g/kg | 8 weeks | Fenofibrate | 0.02 g/kg | [ | ||
| Flavonoids, luteolin and luteoloside | SD rats | 100 mg/kg; 50 mg/kg; 25 mg / kg | 6 weeks | Simvastatin | 10 mg/kg | [ | ||
| 3 | Polyphenols | mice | 50 mg/kg | 11 weeks | / | / | [ | |
| Polyphenols | Wistar rats | 20 mg/Kg | 90 days | / | / | [ | ||
| Polyphenols | SD rats | 10 mg/Kg | 4 weeks | / | / | [ | ||
| Naringin | C57BL/6 J Mice | 25, 50 and 100 mg/kg | 8 weeks | / | / | [ | ||
| 4 | Extract | SD rats | 50 and 100 mg/kg | 4 weeks | / | / | [ | |
| Extract | SD rats | 5% and 10% | 4 weeks | / | / | [ | ||
| Freeze-dried powder | ApoE-/- mice | 1, 2, and 5 g/kg | 12 weeks | / | / | [ | ||
| Concentrated juice | KunMing mice | 10, 15, and 20 ml/kg | 5 weeks | / | / | [ | ||
| Pectin penta-oligogalacturonide | KunMing mice | 300 mg/kg | 4 weeks | / | / | [ | ||
| Crude glycoprotein | KunMing mice | 1.0, 1.5 and 2.0 g/kg | 4 weeks | / | / | [ | ||
| Vitexin | C57BL/6 J mice | 5 mg/kg | 12 weeks | / | / | [ | ||
| Preparation | ApoE − / − mice | / | 16 weeks | / | / | [ | ||
| 5 | Extract | SD rats | 25, 50, and 100 mg/kg | 6 weeks | Metformin | 100 mg/kg | [ | |
| Geniposide | Nrf2 − / − C57BL/6 mice | 50, 75 and 100 mg/kg | 19 h | Fenofibrate | 100 mg/kg | [ | ||
| Geniposide | C57BL/6 and ApoE − / − mice | 50 mg/kg | 13 weeks | / | / | [ | ||
| Geniposide | ApoE − / − mice | 50 mg/kg | 12 weeks | / | / | [ | ||
| Geniposide | ApoE–/– mice | 50 and 100 mg/kg | 4 weeks | / | / | [ | ||
| Genipin | SD rats | 12.5 and 25 mg/kg | 12 days | / | / | [ | ||
| Genipin | C57BL/6 J mice | 5 and 20 mg/kg | 9 weeks | Rosiglitazone | 2 mg/kg | [ | ||
| 6 | Flavonoids | KunMing mice | 100, 200 and 400 mg/kg | 42 days | / | / | [ | |
| Flavonoids | C57BL/6 mice | 100 and 300 mg/kg | 9 weeks | / | / | [ | ||
| Sterol | SD rats | 100, 200 and 400 mg/kg | 42 days | Simvastatin | 3.5 mg/kg | [ | ||
| 7 | Extract | SD rats | 4 g/kg | 4 weeks | / | / | [ | |
| Dried fruit | C57BL/6 J mice | 100 and 300 mg/kg | 3 months | / | / | [ | ||
| Polysaccharides | db/db mice | 200, 500 and 800 mg/kg | 8 weeks | / | / | [ | ||
| Polysaccharides | Wistar rats | 400 mg/kg | 7 weeks | / | / | [ | ||
| 8 | Powder | SD rats | 0.9, 0.6, and 0.3 g/kg | 5 weeks | Atorvastatin | 6.0 mg/kg | [ | |
| Extract | SD rats | 0.5% and 1% | 4 weeks | / | / | [ | ||
| Extract | Wistar rats | 0.5%, 1% and 2% | 10 weeks | / | / | [ | ||
| Flavonoids | db/db mice | 180 mg/kg | 7 weeks | Metformin | 200 mg/kg | [ | ||
| Flavonoids | SD rats | 50, 100 and 200 mg/kg | / | Fenofibrate | 50 mg/kg | [ | ||
| Polyphenols, fiber | SD rats | 0.8, 0.12, 0.48 and 0.6 g/kg | 6 weeks | Orlistat | 0.0324 g/kg | [ | ||
| Extract | C57BL/6 mice | 0.5%, 1.0% and 2.0% | 8 weeks | / | / | [ | ||
| Polysaccharides | C57BL/6 mice | 200, 400 and 800 mg/kg | 8 weeks | Orlistat | 25 mg/kg | [ | ||
| 9 | Powder | SD rats | 600 mg/kg | 18 weeks | / | / | [ | |
| Nuciferine | SD rats | 20 mg/kg | 8 weeks | / | / | [ | ||
| Nuciferine | C57BL/6 mice | 7.5, 15 and 30 mg/kg | 8 weeks | Metformin | 90 mg/kg | [ | ||
| Nuciferine | C57BL/6 J mice | 0.30% | 8 weeks | / | / | [ | ||
| Nuciferine | SD rats | 10 mg/kg | 8 weeks | Simvastatin | 10 mg/kg | [ | ||
| 10 | Extract | SD rats | 5 g/kg | 4 weeks | Simvastatin | 4 mg/kg | [ | |
| Extract | SD rats | 1.25, 2.5 and 5 g/kg | 4 weeks | Simvastatin | 4 mg/kg | [ | ||
| Extract | SD rats | 1.25, 2.5 and 5 g/kg | 6 weeks | Ezetimibe | 1 mg/kg | [ | ||
| Extract | C57BL/6 mice | 5 and 10 g/kg | 12 weeks | Simvastatin | 2 mg/kg | [ | ||
| 11 | Hydroxy- | Wistar rats | 9, 18 and 36 mg/kg | 4 weeks | Fenofibrate | 18 mg/kg | [ | |
| 12 | Diosgenin | Wistar rats | 0.50% | 6 weeks | / | / | [ | |
| Resistant starch | golden hamsters | 0.5, and 1.5 g/100 g | 4 weeks | / | / | [ | ||
| 13 | Extract | SD rats | 1, 2 and 4 g/kg | 14 weeks | Resveratrol | 40 mg/kg | [ | |
| Extract | SD rats | 4 g/kg | 14 weeks | Simvastatin | 1.8 mg/kg | [ | ||
| Polysaccharides | KunMing mice | 200, 400, and 800 mg/kg | 14 days | Simvastatin | 30 mg/kg | [ | ||
| Polysaccharides | SD rats | 120, 240, 480 mg/kg | 14 weeks | Simvastatin | 1.8 mg/kg | [ | ||
| Saponin | ICR mice | 1, 1.5, and 2 g/kg | 4 weeks | Metformin | 0.5 g/kg | [ | ||
| Syringaresinol-di-o-β-d-glucoside | SPF mice | 25, 50 and 75 mg/kg | 2 weeks | / | / | [ | ||
| 14 | Total flavones | C57BL/6 J mice | 5, 25 and 50 mg/kg | 8 weeks | Metformin | 0.15 g/kg | [ | |
| Total flavones | ApoE − / − mice | 10 and 20 mg/kg | 16 weeks | / | / | [ | ||
| Astragaloside IV | SD rats | 80 mg/kg | 8 weeks | Metformin | 200 mg/kg | [ | ||
| 15 | Extract | C5BL/6 mice | 100 and 300 mg/kg | 16 weeks | Metformin | 250 mg/kg | [ | |
| Puerarin | SD rats | 2 g/kg | 16 weeks | / | / | [ | ||
| Puerarin | SD rats | 100 mg/kg | 8 weeks | / | / | [ | ||
| Polysaccharides | db/db mice | 100 and 200 mg/kg | 6 weeks | Rosiglitazone | 10 mg/kg | [ | ||
| PL-S2 | Wistar rats | 50 mg/kg | 3 weeks | Simvastatin | 8 mg/kg | [ | ||
| 16 | Extract | SD rats | 10 g/kg | 4 weeks | Atorvastatin | 10 mg/kg | [ | |
| Extract | SD rats | 54, 162 and 486 mg/kg | 4 weeks | Atorvastatin | 10 mg/kg | [ | ||
| Total aglycones (TA), rubrofusarin-6-β-gentiobioside (RG) and aurantio-obtusin (AO) | C57BL/6 mice | TA 10 g/kg, RG 20 mg/kg, and AO 20 mg/kg | 3 weeks | / | / | [ | ||
| Extract | Wistar rats | 0.5, 1, and 2 g/kg | 6 weeks | Metformin | 0.2 g/kg | [ | ||
| Anthraquinone glycoside | SD rats | 5, 10 and 20 mg/kg | 6 weeks | Polyene phosphatidylcholine | 23 mg/kg | [ | ||
| 1,8-Dihydroxyanthraquinone | mice | 5 mg/kg | 6 weeks | / | / | [ | ||
| 17 | Total terpenoids and total flavonoids | Wistar rats | 400 mg/kg | 3 weeks | Glibenclamide | 5 mg/kg | [ | |
| Protein extract | SD rats | 4 and 6 g/200 g | 2 weeks | / | / | [ | ||
| 18 | Extract | C57BL/6 J mice | 25 mg/kg | 9 weeks | Milk thistle | 100 mg/kg | [ | |
| Extract | C57BL/6 J mice | 25, 50 and 100 mg/kg | 9 weeks | Milk thistle | 100 mg/kg | [ | ||
| 19 | Amygdalin | LDLR-/- mice | 1, 3 and 10 mg/kg | 4 weeks | / | / | [ | |
| Amygdalin | ApoE-/- mice | 0.04 and 0.08 mg/kg | 12 weeks | Simvastatin | 2.57 mg/kg | [ | ||
| Peach kernel oil | ApoE-/- mice | 2 and 5 g/kg | 8 weeks | Simvastatin | 5 mg/kg | [ | ||
| 20 | Extract | Wistar rats | 400 mg/kg | 4 weeks | Atorvastatin | 10 mg/kg | [ | |
| Extract | Wistar rats | 10 g/kg | 4 weeks | / | / | [ | ||
| Extract | albino rats | 5% and 10% | 8 weeks | / | / | [ | ||
| Extract | Wistar rats | 0.50% | 4 weeks | / | / | [ | ||
| Extract | C57BL/6 mice | 5% and 10% | 12 weeks | / | / | [ |
Cell models and interventions of MEPs in the treatment of dyslipidemia
| No | MEPs | Intervention | Cell model | Concentration | Duration | References |
|---|---|---|---|---|---|---|
| 1 | Extract | HUVECs | 50, 100 and 200 μg/mL | 24 h | [ | |
| 2 | Extract | 3T3-L1 cells | 0.85 and 0.56 mg/ml | 5 days | [ | |
| Extract and main components | HepG2 and Caco-2 Cells | 50 and 100 µg/mL | 24 h | [ | ||
| 3 | Extract | 3T3-L1 cells | 50, 100, and 200 ug/mL | 24 h | [ | |
| Vitexin | 3T3-L1 cells | 10 and 50 µM | 8 days | [ | ||
| 4 | Geniposide | HepG2 | 0, 65, 130, 260, 390 and 520 μmol/L | 24 h | [ | |
| Geniposide | HepG2 cells and Caco2 cells | 100 μM | 12 and 24 h | [ | ||
| Geniposide | RAW264.7 macrophage cells | 2.5, 5, 10, 20, 40 and 80 μM | 24 h | [ | ||
| Geniposide | RAW264.7 macrophage cells | 50, 100, and 200 μg/ml | 24 h | [ | ||
| Genipin | Primary hepatocytes | 20 μM | 24 h | [ | ||
| 5 | Flavonoids | HL7702 cells | 5, 10, 20, 40 and 80 μg/mL | 24 h | [ | |
| Kaempferol and kaempferide | HepG2 Cells | 5, 10 and 20 μM | 48 h | [ | ||
| 6 | Extract | 3T3-L1 cells | 10, 50, 100, and 500 ng/mL | 7 days | [ | |
| 7 | Flavonoids | L6 skeletal muscle cells | 5, 10, 20, 40 and 80 µg/ml | 24 h | [ | |
| Flavonoids | HepG2 cells | 1, 5, 10, 30, 60, 90, 150, and 180 μmol /L | 24 h | [ | ||
| Extract | HepG2 cells | 2 mg/mL | 24 h | [ | ||
| Polysaccharides | HepG2 cells | 25, 50, 100, 150 and 200 μg/mL | 24 h | [ | ||
| 8 | Nuciferine | Caco-2 and HT-29 cells | 0, 25, 50, 100 and 200 μM | 24 h | [ | |
| Nuciferine | 3T3-L1 preadipocytes | 0, 2.5, 5, 10 and 20 μM | 24, 48, 72, 96 and 120 h | [ | ||
| Nuciferine | THP-1 cells | 5, 10 and 20 μmol/L | 24 h | [ | ||
| Nuciferine | THP-1 cells | 2.5, 5, 10, and 20 μmol/L | 24 h | [ | ||
| 9 | Diosgenin | C2C12 cells | 0, 20, 40 and 80 μM | 3 h | [ | |
| 10 | Total flavones | HepG2 cells | 0, 2.5, 5, 10, 20 and 40 μg/ml | 24 h | [ | |
| Total flavones | HUVECs, RAW264.7, THP-1 cells and peritoneal macrophages | 6, 12 and 24 μg/ml | 12 h | [ | ||
| Astragaloside iv | HepG2 cells | 50, 100, and 200 μg/mL | 24 h | [ | ||
| 11 | Extract | C2C12 cells | 0.2 and 0.5 mg/mL | 24 h | [ | |
| Puerarin | HepG2 cells | 75 and 150 μM | 24 h | [ | ||
| 12 | Extract | 3T3-L1 cells | 100, 200, 400, and 1000 μg/mL | 48 h | [ | |
| 13 | Amygdalin | bone marrow-derived macrophages | 25, 50, 100, 200, 400, and 800 μg/ml | 24 h | [ | |
| Peach kernel oil | HUVECs and RAW264.7 macrophage cells | 0.01, 0.05, 0.1, 0.15, and 0.2 μg/mL; 50, 100 and 200 µg/mL | 24 h | [ |
Fig. 3MEPs have the dual properties and advantages of medicine and food. In addition to regulating metabolism, MEPs also have other beneficial effects and can protect from cardiovascular diseases, which have great potential for the development of new drugs, complementary therapies and functional foods